Sugi Predict

Sugi Predict / Compounds / SCHEMBL7295446

SCHEMBL7295446

SCHEMBL7295446

CC(=O)SC1CN(C(=O)OCc2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ RAB9A P51151 2/20 0.53
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ HTR2C P28335 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ HTT P42858 1/20 0.46
▸ CHRM4 P08173 1/20 0.44
▸ GRIN2B Q13224 2/20 0.44
▸ HTR1A P08908 1/20 0.44
▸ ADRA2A P08913 1/20 0.44
▸ ADRA2B P18089 1/20 0.44
▸ ADRA2C P18825 1/20 0.44
▸ DRD1 P21728 1/20 0.44
▸ HRH2 P25021 1/20 0.44
▸ HTR1B P28222 1/20 0.44
▸ HTR2A P28223 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11931619 0.90 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL21806036 0.90 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL1103931 0.90 SMN1; SMN2 (0.59) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL4349202 0.87 SMN1; SMN2 (0.53) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL5234494 0.86 SMN1; SMN2 (0.65) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL20634347 0.83 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL31726704 0.82 SMN1; SMN2 (0.47) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL21098130 0.81 SMN1; SMN2 (0.61) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL16472423 0.81 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL14372548 0.81 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583868-B2 JAK inhibitors and methods for synthesizing and using thereof Galderma Holding SA (CH) 2026-03-24 — — US disclosed
EP-4327809-A2 TYK2 INHIBITORS AND USES THEREOF Takeda Pharmaceutical Company Limited (JP) 2024-02-28 — — EP disclosed
CN-117015543-A Novel JAK inhibitor compounds, methods of synthesis and uses thereof 高德美控股有限公司 2023-11-07 — — CN disclosed
EP-3344624-B1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI INC (US) 2023-10-25 — — EP disclosed
EP-4210827-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHOD FOR SYNTHESIZING SAME AND USE THEREOF Galderma Holding SA (CH) 2023-07-19 — — EP disclosed
US-20230212188-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF Galderma Holding SA (CH) 2023-07-06 — — US disclosed
US-20230212188-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF Galderma Holding SA (CH) 2023-07-06 — — US disclosed
US-20230212188-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF Galderma Holding SA (CH) 2023-07-06 — — US disclosed
US-20220267260-A1 COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS Epizyme, Inc. 2022-08-25 — — US disclosed
US-20220117945-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF NOVARTIS AG (CH) 2022-04-21 — — US disclosed
WO-2018102419-A1 COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS Epizyme, Inc. (US) 2018-06-07 — — WO disclosed
US-20170066763-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-09 — — US disclosed
US-20170066763-A1 TYK2 INHIBITORS AND USES THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-09 — — US disclosed
WO-2017040757-A1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI, INC. (US) 2017-03-09 — — WO disclosed
US-5258362-A Enzyme inhibitors, amides with oxetane ring ABBOTT LABORATORIES (US) 1993-11-02 — — US disclosed
US-5063208-A Cardiovascular disorders, vision defects ABBOTT LABORATORIES (US) 1991-11-05 — — US disclosed
EP-0416393-A1 Peptidyl difluorodiol renin inhibitors ABBOTT LABORATORIES (US) 1991-03-13 — — EP disclosed
EP-0410260-A2 Peptidyl aminodiol renin inhibitors ABBOTT LABORATORIES (US) 1991-01-30 — — EP disclosed
WO-1989010751-A1 FUNCTIONALIZED PEPTIDYL AMINODIOLS AND -TRIOLS ABBOTT LABORATORIES (US) 1989-11-16 — — WO disclosed
EP-0341602-A2 Renin-inhibiting functionalized peptidyl aminodiols and - triols ABBOTT LABORATORIES (US) 1989-11-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170066763-A1 TYK2 INHIBITORS AND USES THEREOF TYK2, JAK2, JAK1 SMN1; SMN2 1145/4885NPC1 4595/4885RAB9A 3462/4885
US-20220267260-A1 COMPOUNDS CONTAINING A SULFONIC GROUP AS KAT INHIBITORS KAT5, KAT2A, KAT7 SMN1; SMN2 4164/4885NPC1 494/4885RAB9A 3777/4885
US-20230212188-A1 NOVEL JAK INHIBITOR COMPOUNDS, METHODS FOR SYNTHESIZING SAME AND USE THEREOF JAK1, JAK2, JAK3 SMN1; SMN2 3503/4885NPC1 2308/4885RAB9A 1101/4885
US-20220117945-A1 ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF SLC26A4, SLC26A3, ALDH5A1 SMN1; SMN2 762/4885NPC1 1447/4885RAB9A 1566/4885
US-12583868-B2 JAK inhibitors and methods for synthesizing and using thereof JAK2, JAK1, JAK3 SMN1; SMN2 3049/4885NPC1 911/4885RAB9A 2358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback